|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: LEO1 |
Gene summary for LEO1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | LEO1 | Gene ID | 123169 |
| Gene name | LEO1 homolog, Paf1/RNA polymerase II complex component | |
| Gene Alias | RDL | |
| Cytomap | 15q21.2 | |
| Gene Type | protein-coding | GO ID | GO:0001704 | UniProtAcc | Q8WVC0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 123169 | LEO1 | LZE4T | Human | Esophagus | ESCC | 1.30e-14 | 3.79e-01 | 0.0811 |
| 123169 | LEO1 | LZE6T | Human | Esophagus | ESCC | 3.53e-03 | 1.40e-01 | 0.0845 |
| 123169 | LEO1 | P1T-E | Human | Esophagus | ESCC | 3.43e-09 | 3.20e-01 | 0.0875 |
| 123169 | LEO1 | P2T-E | Human | Esophagus | ESCC | 4.19e-15 | 1.75e-01 | 0.1177 |
| 123169 | LEO1 | P4T-E | Human | Esophagus | ESCC | 4.07e-29 | 6.53e-01 | 0.1323 |
| 123169 | LEO1 | P5T-E | Human | Esophagus | ESCC | 3.04e-21 | 4.34e-01 | 0.1327 |
| 123169 | LEO1 | P8T-E | Human | Esophagus | ESCC | 1.55e-23 | 3.95e-01 | 0.0889 |
| 123169 | LEO1 | P9T-E | Human | Esophagus | ESCC | 1.25e-11 | 2.85e-01 | 0.1131 |
| 123169 | LEO1 | P10T-E | Human | Esophagus | ESCC | 3.21e-32 | 5.75e-01 | 0.116 |
| 123169 | LEO1 | P11T-E | Human | Esophagus | ESCC | 2.97e-08 | 1.97e-01 | 0.1426 |
| 123169 | LEO1 | P12T-E | Human | Esophagus | ESCC | 4.04e-18 | 3.82e-01 | 0.1122 |
| 123169 | LEO1 | P15T-E | Human | Esophagus | ESCC | 7.49e-18 | 4.15e-01 | 0.1149 |
| 123169 | LEO1 | P16T-E | Human | Esophagus | ESCC | 1.27e-17 | 3.13e-01 | 0.1153 |
| 123169 | LEO1 | P19T-E | Human | Esophagus | ESCC | 4.08e-03 | 5.62e-01 | 0.1662 |
| 123169 | LEO1 | P20T-E | Human | Esophagus | ESCC | 3.83e-11 | 1.56e-01 | 0.1124 |
| 123169 | LEO1 | P21T-E | Human | Esophagus | ESCC | 2.40e-16 | 2.81e-01 | 0.1617 |
| 123169 | LEO1 | P22T-E | Human | Esophagus | ESCC | 4.96e-28 | 2.10e-01 | 0.1236 |
| 123169 | LEO1 | P23T-E | Human | Esophagus | ESCC | 6.02e-14 | 2.83e-01 | 0.108 |
| 123169 | LEO1 | P24T-E | Human | Esophagus | ESCC | 1.82e-13 | 3.08e-01 | 0.1287 |
| 123169 | LEO1 | P26T-E | Human | Esophagus | ESCC | 9.26e-18 | 4.18e-01 | 0.1276 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00074926 | Esophagus | ESCC | endoderm development | 54/8552 | 77/18723 | 1.20e-05 | 1.12e-04 | 54 |
| GO:00311233 | Esophagus | ESCC | RNA 3'-end processing | 76/8552 | 116/18723 | 1.25e-05 | 1.15e-04 | 76 |
| GO:00063783 | Esophagus | ESCC | mRNA polyadenylation | 33/8552 | 44/18723 | 7.30e-05 | 5.49e-04 | 33 |
| GO:00335234 | Esophagus | ESCC | histone H2B ubiquitination | 12/8552 | 12/18723 | 8.21e-05 | 6.01e-04 | 12 |
| GO:00436313 | Esophagus | ESCC | RNA polyadenylation | 33/8552 | 45/18723 | 1.54e-04 | 1.02e-03 | 33 |
| GO:005068514 | Esophagus | ESCC | positive regulation of mRNA processing | 25/8552 | 32/18723 | 1.84e-04 | 1.17e-03 | 25 |
| GO:00017064 | Esophagus | ESCC | endoderm formation | 38/8552 | 54/18723 | 2.08e-04 | 1.31e-03 | 38 |
| GO:00017044 | Esophagus | ESCC | formation of primary germ layer | 75/8552 | 121/18723 | 2.17e-04 | 1.36e-03 | 75 |
| GO:1903706110 | Esophagus | ESCC | regulation of hemopoiesis | 201/8552 | 367/18723 | 2.60e-04 | 1.58e-03 | 201 |
| GO:00359873 | Esophagus | ESCC | endodermal cell differentiation | 32/8552 | 45/18723 | 4.87e-04 | 2.70e-03 | 32 |
| GO:003296812 | Esophagus | ESCC | positive regulation of transcription elongation from RNA polymerase II promoter | 12/8552 | 13/18723 | 6.18e-04 | 3.32e-03 | 12 |
| GO:0045637111 | Esophagus | ESCC | regulation of myeloid cell differentiation | 118/8552 | 210/18723 | 1.35e-03 | 6.43e-03 | 118 |
| GO:190331121 | Liver | HCC | regulation of mRNA metabolic process | 205/7958 | 288/18723 | 3.38e-23 | 6.90e-21 | 205 |
| GO:005068421 | Liver | HCC | regulation of mRNA processing | 106/7958 | 137/18723 | 7.64e-17 | 7.12e-15 | 106 |
| GO:001657021 | Liver | HCC | histone modification | 283/7958 | 463/18723 | 2.68e-16 | 2.33e-14 | 283 |
| GO:190331321 | Liver | HCC | positive regulation of mRNA metabolic process | 85/7958 | 118/18723 | 7.10e-11 | 2.56e-09 | 85 |
| GO:00311241 | Liver | HCC | mRNA 3'-end processing | 50/7958 | 62/18723 | 8.44e-10 | 2.60e-08 | 50 |
| GO:00311231 | Liver | HCC | RNA 3'-end processing | 81/7958 | 116/18723 | 2.27e-09 | 6.32e-08 | 81 |
| GO:019873821 | Liver | HCC | cell-cell signaling by wnt | 247/7958 | 446/18723 | 2.11e-08 | 4.96e-07 | 247 |
| GO:00314401 | Liver | HCC | regulation of mRNA 3'-end processing | 26/7958 | 28/18723 | 2.82e-08 | 6.43e-07 | 26 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| LEO1 | SNV | Missense_Mutation | c.1512N>A | p.Met504Ile | p.M504I | Q8WVC0 | protein_coding | tolerated(0.08) | possibly_damaging(0.69) | TCGA-AN-A0FT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| LEO1 | SNV | Missense_Mutation | novel | c.43N>A | p.Glu15Lys | p.E15K | Q8WVC0 | protein_coding | deleterious_low_confidence(0.01) | benign(0.031) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| LEO1 | SNV | Missense_Mutation | c.68C>T | p.Ser23Phe | p.S23F | Q8WVC0 | protein_coding | tolerated_low_confidence(0.1) | probably_damaging(0.991) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| LEO1 | deletion | Frame_Shift_Del | novel | c.233delN | p.Asp78ValfsTer27 | p.D78Vfs*27 | Q8WVC0 | protein_coding | TCGA-A7-A3J0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrazole | SD | ||
| LEO1 | insertion | Nonsense_Mutation | novel | c.144_145insATTAATTATATTTTGATCCTATCTTCTTAGCTTAAATATGAGGGCA | p.Glu49IlefsTer10 | p.E49Ifs*10 | Q8WVC0 | protein_coding | TCGA-A8-A0A1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| LEO1 | SNV | Missense_Mutation | c.1168N>C | p.Asp390His | p.D390H | Q8WVC0 | protein_coding | deleterious(0.04) | probably_damaging(0.913) | TCGA-LP-A4AW-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| LEO1 | SNV | Missense_Mutation | c.1033C>G | p.Gln345Glu | p.Q345E | Q8WVC0 | protein_coding | tolerated(0.86) | benign(0.003) | TCGA-LP-A7HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| LEO1 | SNV | Missense_Mutation | c.1505G>C | p.Arg502Thr | p.R502T | Q8WVC0 | protein_coding | deleterious(0) | probably_damaging(0.953) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| LEO1 | SNV | Missense_Mutation | rs767042967 | c.862N>T | p.Arg288Cys | p.R288C | Q8WVC0 | protein_coding | deleterious(0.01) | possibly_damaging(0.543) | TCGA-A6-6654-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | oxaliplatin | SD |
| LEO1 | SNV | Missense_Mutation | rs751561202 | c.1595N>A | p.Arg532His | p.R532H | Q8WVC0 | protein_coding | deleterious(0.02) | benign(0.007) | TCGA-A6-6782-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |